Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1969 12
1970 1
1971 4
1972 3
1973 3
1974 6
1975 8
1976 6
1977 11
1978 3
1979 4
1980 12
1981 9
1982 12
1983 9
1984 8
1985 6
1986 4
1987 2
1988 4
1989 3
1990 6
1991 8
1992 13
1993 10
1994 10
1995 8
1996 21
1997 20
1998 22
1999 17
2000 17
2001 13
2002 15
2003 14
2004 15
2005 26
2006 12
2007 10
2008 6
2009 4
2010 1
2011 1
2012 3
2013 5
2014 2
2015 3
2016 1
2019 1
2020 2
2021 1
2022 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

408 results

Results by year

Filters applied: . Clear all
Page 1
PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells.
Codarri Deak L, Nicolini V, Hashimoto M, Karagianni M, Schwalie PC, Lauener L, Varypataki EM, Richard M, Bommer E, Sam J, Joller S, Perro M, Cremasco F, Kunz L, Yanguez E, Hüsser T, Schlenker R, Mariani M, Tosevski V, Herter S, Bacac M, Waldhauer I, Colombetti S, Gueripel X, Wullschleger S, Tichet M, Hanahan D, Kissick HT, Leclair S, Freimoser-Grundschober A, Seeber S, Teichgräber V, Ahmed R, Klein C, Umaña P. Codarri Deak L, et al. Among authors: seeber s. Nature. 2022 Oct;610(7930):161-172. doi: 10.1038/s41586-022-05192-0. Epub 2022 Sep 28. Nature. 2022. PMID: 36171284 Free PMC article.
Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumors.
Natoli M, Hatje K, Gulati P, Junker F, Herzig P, Jiang Z, Davydov II, Germann M, Trüb M, Marbach D, Zwick A, Weber P, Seeber S, Wiese M, Lardinois D, Heinzelmann-Schwarz V, Rosenberg R, Tietze L, Mertz KD, Umaña P, Klein C, Codarri-Deak L, Kao H, Zippelius A. Natoli M, et al. Among authors: seeber s. J Immunother Cancer. 2022 Nov;10(11):e005548. doi: 10.1136/jitc-2022-005548. J Immunother Cancer. 2022. PMID: 36319064 Free PMC article.
Hematoprotection by transfer of drug-resistance genes.
Flasshove M, Moritz T, Bardenheuer W, Seeber S. Flasshove M, et al. Among authors: seeber s. Acta Haematol. 2003;110(2-3):93-106. doi: 10.1159/000072458. Acta Haematol. 2003. PMID: 14583669 Review.
Raf kinase inhibitors in oncology.
Strumberg D, Seeber S. Strumberg D, et al. Among authors: seeber s. Onkologie. 2005 Feb;28(2):101-7. doi: 10.1159/000083373. Onkologie. 2005. PMID: 15665559 Review.
Comparative activity of ifosfamide and cyclophosphamide.
Brade W, Seeber S, Herdrich K. Brade W, et al. Among authors: seeber s. Cancer Chemother Pharmacol. 1986;18 Suppl 2:S1-9. doi: 10.1007/BF00647438. Cancer Chemother Pharmacol. 1986. PMID: 3545522 Review.
[Liposarcoma].
Seeber S. Seeber S. Dtsch Med Wochenschr. 1987 Oct 9;112(41):1594-5. Dtsch Med Wochenschr. 1987. PMID: 3665743 German. No abstract available.
408 results